Corvus Pharmaceuticals

Company snapshot

Corvus is a unique environment for exceptional individuals who want to learn, contribute to an exceptional team, and make a difference in the lives of people with cancer. At Corvus, we take pride in our collaborative, community-based culture. We understand that the most successful teams are those that learn from each other and co-create in an environment that nurtures open, transparent communicati

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Corvus Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 40

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Apogee Therapeutics

  TA overlap score 21.6

• Peer + 0 momentum

  Qilu Pharmaceuticals

  TA overlap score 20.4

Recent activity

Latest pipeline, patent, and corporate events for Corvus Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   CPI-006 — Phase 1

2. Jun 8, 2026 Clinical update

   CPI-006 2 mg/kg + SOC — Phase 3

3. Jun 5, 2026 Clinical update

   Soquelitinib — Phase 3

4. Jun 5, 2026 Clinical update

   CPI-818 — Phase 1

5. Jun 5, 2026 Clinical update

   CPI-444 Capsules — Phase 1

View all clinical trial activity →

• What is Corvus Pharmaceuticals?

  Corvus Pharmaceuticals is a pharma organization headquartered in Burlingame, USA. It trades on NYSE under ticker CRVS. Primary therapeutic focus areas include Multiple Myeloma, Renal Cell Cancer, Covid-19, COVID-19, Non-Small Cell Lung Cancer. NovaPharmaNews links 9 clinical prog

• Is Corvus Pharmaceuticals publicly traded?

  Yes. Corvus Pharmaceuticals is listed with ticker CRVS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Corvus Pharmaceuticals develop or market?

  We link 4 drug profile(s) where Corvus Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/corvus-pharmaceuticals#company-drugs.

• What are the latest developments for Corvus Pharmaceuticals?

  In the last 12 months our linked public records show 9 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Corvus Pharmaceuticals focus on?

  Corvus Pharmaceuticals focuses on Multiple Myeloma, Renal Cell Cancer, Covid-19 based on our analysis of their pipeline programs and drug development activities.